Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients

Table 2

Changes in the lipids profile.

	1-year median (Q1-Q3)	Change from the baseline mean (95% CI)	value
Triglycerides (mmol/L)	1.09 (0.80, 1.57)	−0.77 (−1.56, 0.22)	= 0.0312
Total cholesterol (mmol/L)	2.26 (2.11, 2.45)	−2.50 (−2.98, −2.02)	= 0.0003
HDL cholesterol (mmol/L)	1.06 (0.94, 1.11)	−0.13 (−0.23, 0.03)	= 0.0191
LDL cholesterol (mmol/L)	0.95 (0.85, 1.16)	−2.01 (−2.46, −1.57)	= 0.0003
AI	1.31 (0.90, 1.43)	−1.86 (−2.17, −1.56)	= 0.0003

Compared with baseline using Wilcoxon signed-rank test.